GlassScriptPhysician profile
Suresh Gupta
NPI 1346272929
$2,564.30
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $299 · 2021: $583 · 2022: $449 · 2023: $589 · 2024: $70.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $753.62 | 2019-2024 | Proclaim |
| Abbvie INC. | $384.98 | 2023 | |
| Amgen INC. | $318.60 | 2019-2022 | |
| Allergan, INC. | $184.23 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $112.05 | 2019-2021 | |
| Galderma Laboratories, L.P. | $95.30 | 2023 | |
| Vertiflex, INC. | $82.52 | 2019 | |
| Pfizer INC. | $79.58 | 2020-2021 | |
| Medtronic, INC. | $72.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $56.66 | 2019-2020 | |
| Curonix LLC | $56.10 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Medtronic Vascular, INC. | $48.52 | 2019 | |
| Vertos Medical, INC. | $40.57 | 2020-2024 | Mild Device Kit |
| Boston Scientific Corporation | $36.33 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $35.12 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $27.66 | 2019 | |
| Mindray Ds USA, INC. | $25.92 | 2024 | A7 Anesthesia System |
| Alcon Vision LLC | $20.86 | 2022 | |
| Convatec INC. | $19.79 | 2023 | |
| Averitas Pharma INC. | $19.17 | 2023 | Qutenza |
| Angiodynamics, INC. | $15.80 | 2022 | |
| Lilly USA, LLC | $15.27 | 2021 | |
| Redhill Biopharma INC. | $14.50 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.86 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.59 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.72 | 2019 | |
| Daiichi Sankyo INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.